Pr Alexander Eggermont presented the initial efficacy and safety results from EORTC trial 18071 at ASCO 2014 in Chicago
11 Jun 2014
Vaccination with GM2-KLH-QS21 does not improve outcome stage II melanomas patients in EORTC study
13 Sep 2013
EORTC Melanoma Group study selects AS15 adjuvant for active immunization with MAGE A3 protein for treatment of metastatic melanoma
29 May 2013
Gender plays a role in progression-free and disease-specific survival according to five EORTC studies in stage III-IV melanoma patients
23 May 2013
EORTC Melanoma Group investigating use of PEG-IFN- α-2b for patients with stage II ulcerated primary cutaneous melanoma
16 Jan 2013
Abstracts accepted for the 2011 ASCO Annual Meeting
28 Apr 2011
Sylatron™ receives FDA approval based on the EORTC 18991 trial
28 Apr 2011
Abstracts accepted for the 2010 ASCO Annual Meeting
26 May 2010